VENTURE (12+ years), TRAVERSE OLE (12+ years)
86% of patients reduced or eliminated their OCS dose at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) (ITT population, VENTURE).13
A 70% significant reduction in OCS dose (median 100%) from baseline was observed at Week 24 with DUPIXENT 300 mg Q2W + SOC (n=103) (95% CI: 60%, 80%) vs 42% (median 50%) with placebo + SOC (n=107) (primary endpoint).1
In addition, 79% of patients from VENTURE eliminated their OCS dose at Week 96 in the TRAVERSE OLE study (secondary endpoint).9
Results are descriptive. Definitive conclusions cannot be made. Data were not multiplicity controlled and there are limitations associated with open-label study design, including lack of comparator arm, decreasing sample size, and potential continued involvement of responders and attrition of non-responders.
dOCS reduction was at investigators’ discretion.9